ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sanofi-Aventis Strikes Two Deals

by Ann M. Thayer
October 4, 2010 | APPEARED IN VOLUME 88, ISSUE 40

Sanofi-Aventis and its Sanofi Pasteur vaccines division will work with the German biotech firm Pieris. The goal is to develop drug candidates from Pieris’ library of low-molecular-weight proteins, called anticalins, against at least two disease targets. Sanofi will pay $4.8 million up front, as well as provide R&D funding and milestone payments. For each resulting product, Pieris could receive up to $60 million. Separately, Sanofi Pasteur will acquire Orlando, Fla.-based VaxDesign for $55 million. Initially supported by government defense funding, VaxDesign has developed in vitro models of the human immune system that can be used instead of animal models.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment